speb/financial-data huggingface dataset:
BIO.B balance_sheet (annual, 2023-12-31) — Tangible Book Value: 8007100000.00
BIO.B income_statement (annual, 2023-12-31) — Tax Effect Of Unusual Items: -310450000.00
BIO.B income_statement (annual, 2023-12-31) — Tax Provision: -212800000.00
BIO.B income_statement (annual, 2023-12-31) — Tax Rate For Calcs: 0.25
BIO.B balance_sheet (annual, 2023-12-31) — Total Assets: 12299100000.00
BIO.B balance_sheet (annual, 2023-12-31) — Total Capitalization: 9940300000.00
BIO.B balance_sheet (annual, 2023-12-31) — Total Debt: 1405500000.00
BIO.B balance_sheet (annual, 2023-12-31) — Total Equity Gross Minority Interest: 8741200000.00
BIO.B income_statement (annual, 2023-12-31) — Total Expenses: 2333400000.00
BIO.B balance_sheet (annual, 2023-12-31) — Total Liabilities Net Minority Interest: 3557900000.00
BIO.B balance_sheet (annual, 2023-12-31) — Total Non Current Assets: 9250800000.00
BIO.B balance_sheet (annual, 2023-12-31) — Total Non Current Liabilities Net Minority Interest: 3035100000.00
BIO.B income_statement (annual, 2023-12-31) — Total Operating Income As Reported: 337800000.00
BIO.B balance_sheet (annual, 2023-12-31) — Total Tax Payable: 35800000.00
BIO.B income_statement (annual, 2023-12-31) — Total Unusual Items: -1241800000.00
BIO.B income_statement (annual, 2023-12-31) — Total Unusual Items Excluding Goodwill: -1241800000.00
BIO.B balance_sheet (annual, 2023-12-31) — Treasury Shares Number: 1747438.00
BIO.B balance_sheet (annual, 2023-12-31) — Treasury Stock: 632500000.00
BIO.B cash_flow (annual, 2023-12-31) — Unrealized Gain Loss On Investment Securities: 1252300000.00
BIO.B balance_sheet (annual, 2023-12-31) — Work In Process: 246000000.00
BIO.B balance_sheet (annual, 2023-12-31) — Working Capital: 2525500000.00
BIO.B income_statement (annual, 2023-12-31) — Write Off: 0.00
BIO.B income_statement (quarterly, 2024-09-30) — Gain On Sale Of Business: 0.00
BIO.B cash_flow (quarterly, 2024-09-30) — Net Other Financing Charges: -3100000.00
BIO.B balance_sheet (quarterly, 2024-09-30) — Other Inventories: -24000.00
BIO.B balance_sheet (quarterly, 2024-09-30) — Restricted Cash: 5560000.00
BIO.B income_statement (quarterly, 2024-09-30) — Special Income Charges: 0.00
BIO.B income_statement (annual, 2024-12-31) — +Operating Expense: 1109900000.00
BIO.B income_statement (annual, 2024-12-31) — +Total Revenue: 2566500000.00
BIO.B balance_sheet (annual, 2024-12-31) — Accounts Payable: 122300000.00
BIO.B balance_sheet (annual, 2024-12-31) — Accounts Receivable: 452500000.00
BIO.B balance_sheet (annual, 2024-12-31) — Accumulated Depreciation: -1109200000.00
BIO.B balance_sheet (quarterly, 2024-12-31) — Accumulated Depreciation: -1109200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Additional Paid In Capital: 463200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Allowance For Doubtful Accounts Receivable: -9200000.00
BIO.B cash_flow (annual, 2024-12-31) — Asset Impairment Charge: 0.00
BIO.B income_statement (annual, 2024-12-31) — Basic Average Shares: 28214000.00
BIO.B income_statement (quarterly, 2024-12-31) — Basic Average Shares: 27997000.00
BIO.B income_statement (annual, 2024-12-31) — Basic EPS: -65.36
BIO.B income_statement (quarterly, 2024-12-31) — Basic EPS: -25.57
BIO.B cash_flow (annual, 2024-12-31) — Beginning Cash Position: 404400000.00
BIO.B balance_sheet (annual, 2024-12-31) — Buildings And Improvements: 426300000.00
BIO.B balance_sheet (quarterly, 2024-12-31) — Buildings And Improvements: 426300000.00
BIO.B cash_flow (annual, 2024-12-31) — Capital Expenditure: -189000000.00
BIO.B balance_sheet (annual, 2024-12-31) — Capital Lease Obligations: 173100000.00
BIO.B balance_sheet (annual, 2024-12-31) — Capital Stock: 0.00
BIO.B balance_sheet (annual, 2024-12-31) — Cash And Cash Equivalents: 488100000.00
BIO.B balance_sheet (annual, 2024-12-31) — Cash Cash Equivalents And Short Term Investments: 1664500000.00
BIO.B cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Financing Activities: -218800000.00
BIO.B cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Investing Activities: -160200000.00
BIO.B cash_flow (annual, 2024-12-31) — Cash Flow From Continuing Operating Activities: 455200000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Account Payable: -40900000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Income Tax Payable: 24100000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Inventory: 8500000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Other Current Assets: -7500000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Other Current Liabilities: 5600000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Other Working Capital: -626800000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Payable: -16800000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Payables And Accrued Expense: -16800000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Receivables: 16200000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Tax Payable: 24100000.00
BIO.B cash_flow (annual, 2024-12-31) — Change In Working Capital: -620800000.00
BIO.B cash_flow (annual, 2024-12-31) — Changes In Account Receivables: 16200000.00
BIO.B cash_flow (annual, 2024-12-31) — Changes In Cash: 76200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Common Stock: 0.00
BIO.B balance_sheet (annual, 2024-12-31) — Common Stock Equity: 6569300000.00
BIO.B cash_flow (annual, 2024-12-31) — Common Stock Payments: -203600000.00
BIO.B income_statement (annual, 2024-12-31) — Cost Of Revenue: 1187600000.00
BIO.B balance_sheet (annual, 2024-12-31) — Current Accrued Expenses: 124200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Current Assets: 3030300000.00
BIO.B balance_sheet (annual, 2024-12-31) — Current Capital Lease Obligation: 41700000.00
BIO.B balance_sheet (annual, 2024-12-31) — Current Debt: 1200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Current Debt And Capital Lease Obligation: 42900000.00
BIO.B balance_sheet (annual, 2024-12-31) — Current Liabilities: 467800000.00
BIO.B cash_flow (annual, 2024-12-31) — Depreciation Amortization Depletion: 151600000.00
BIO.B cash_flow (annual, 2024-12-31) — Depreciation And Amortization: 151600000.00
BIO.B income_statement (annual, 2024-12-31) — Diluted Average Shares: 28214000.00
BIO.B income_statement (quarterly, 2024-12-31) — Diluted Average Shares: 27997000.00
BIO.B income_statement (annual, 2024-12-31) — Diluted EPS: -65.36
BIO.B income_statement (quarterly, 2024-12-31) — Diluted EPS: -25.57
BIO.B income_statement (annual, 2024-12-31) — Diluted NI Availto Com Stockholders: -1844200000.00
BIO.B income_statement (annual, 2024-12-31) — EBIT: -2293600000.00
BIO.B income_statement (annual, 2024-12-31) — EBITDA: -2142000000.00
BIO.B cash_flow (annual, 2024-12-31) — Effect Of Exchange Rate Changes: 9200000.00
BIO.B cash_flow (annual, 2024-12-31) — End Cash Position: 489800000.00
BIO.B cash_flow (annual, 2024-12-31) — Financing Cash Flow: -218800000.00
BIO.B balance_sheet (annual, 2024-12-31) — Finished Goods: 294800000.00
BIO.B cash_flow (annual, 2024-12-31) — Free Cash Flow: 266200000.00
BIO.B cash_flow (annual, 2024-12-31) — Gain Loss On Sale Of Business: 0.00
BIO.B income_statement (annual, 2024-12-31) — Gain On Sale Of Business: 0.00
BIO.B income_statement (quarterly, 2024-12-31) — Gain On Sale Of Business: 0.00
BIO.B income_statement (annual, 2024-12-31) — Gain On Sale Of Security: -2646200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Gains Losses Not Affecting Retained Earnings: -538200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Goodwill: 410500000.00
BIO.B balance_sheet (annual, 2024-12-31) — Goodwill And Other Intangible Assets: 704100000.00
BIO.B balance_sheet (annual, 2024-12-31) — Gross Accounts Receivable: 461700000.00
BIO.B balance_sheet (annual, 2024-12-31) — Gross PPE: 1797800000.00
BIO.B income_statement (annual, 2024-12-31) — Gross Profit: 1378900000.00
BIO.B income_statement (annual, 2024-12-31) — Impairment Of Capital Assets: 0.00
BIO.B income_statement (annual, 2024-12-31) — Interest Expense: 48900000.00
BIO.B income_statement (annual, 2024-12-31) — Interest Expense Non Operating: 48900000.00
BIO.B income_statement (annual, 2024-12-31) — Interest Income: 82000000.00
BIO.B income_statement (annual, 2024-12-31) — Interest Income Non Operating: 82000000.00
BIO.B balance_sheet (annual, 2024-12-31) — Inventory: 760000000.00
BIO.B balance_sheet (annual, 2024-12-31) — Invested Capital: 7770900000.00
BIO.B cash_flow (annual, 2024-12-31) — Investing Cash Flow: -160200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Investments And Advances: 4839200000.00
BIO.B cash_flow (annual, 2024-12-31) — Issuance Of Debt: 0.00
BIO.B balance_sheet (annual, 2024-12-31) — Land And Improvements: 27800000.00
BIO.B balance_sheet (quarterly, 2024-12-31) — Land And Improvements: 27800000.00
BIO.B balance_sheet (annual, 2024-12-31) — Long Term Capital Lease Obligation: 131400000.00
BIO.B balance_sheet (annual, 2024-12-31) — Long Term Debt: 1200400000.00
BIO.B balance_sheet (annual, 2024-12-31) — Long Term Debt And Capital Lease Obligation: 1331800000.00
BIO.B cash_flow (annual, 2024-12-31) — Long Term Debt Issuance: 0.00
BIO.B cash_flow (annual, 2024-12-31) — Long Term Debt Payments: -400000.00
BIO.B cash_flow (annual, 2024-12-31) — Net Business Purchase And Sale: 0.00
BIO.B cash_flow (annual, 2024-12-31) — Net Common Stock Issuance: -203600000.00
BIO.B balance_sheet (annual, 2024-12-31) — Net Debt: 713500000.00
BIO.B income_statement (annual, 2024-12-31) — Net Income: -1844200000.00
BIO.B income_statement (annual, 2024-12-31) — Net Income Common Stockholders: -1844200000.00
BIO.B income_statement (annual, 2024-12-31) — Net Income Continuous Operations: -1844200000.00
BIO.B income_statement (annual, 2024-12-31) — Net Income From Continuing And Discontinued Operation: -1844200000.00
BIO.B income_statement (annual, 2024-12-31) — Net Income From Continuing Operation Net Minority Interest: -1844200000.00
BIO.B cash_flow (annual, 2024-12-31) — Net Income From Continuing Operations: -1844200000.00
BIO.B income_statement (annual, 2024-12-31) — Net Income Including Noncontrolling Interests: -1844200000.00
BIO.B cash_flow (annual, 2024-12-31) — Net Intangibles Purchase And Sale: -23400000.00
BIO.B cash_flow (quarterly, 2024-12-31) — Net Intangibles Purchase And Sale: 10000.00
BIO.B income_statement (annual, 2024-12-31) — Net Interest Income: 33100000.00
BIO.B cash_flow (annual, 2024-12-31) — Net Investment Purchase And Sale: 28700000.00
BIO.B cash_flow (annual, 2024-12-31) — Net Issuance Payments Of Debt: -400000.00
BIO.B cash_flow (annual, 2024-12-31) — Net Long Term Debt Issuance: -400000.00
BIO.B income_statement (annual, 2024-12-31) — Net Non Operating Interest Income Expense: 33100000.00
BIO.B cash_flow (annual, 2024-12-31) — Net Other Financing Charges: -34000000.00
BIO.B cash_flow (quarterly, 2024-12-31) — Net Other Financing Charges: -30103000.00
BIO.B balance_sheet (annual, 2024-12-31) — Net PPE: 688600000.00
BIO.B cash_flow (annual, 2024-12-31) — Net PPE Purchase And Sale: -165500000.00
BIO.B balance_sheet (annual, 2024-12-31) — Net Tangible Assets: 5865200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Non Current Deferred Liabilities: 818000000.00
BIO.B balance_sheet (annual, 2024-12-31) — Non Current Deferred Taxes Liabilities: 818000000.00
BIO.B income_statement (annual, 2024-12-31) — Normalized EBITDA: 504200000.00
BIO.B income_statement (annual, 2024-12-31) — Normalized Income: 239096495.20
BIO.B cash_flow (annual, 2024-12-31) — Operating Cash Flow: 455200000.00
BIO.B income_statement (annual, 2024-12-31) — Operating Income: 269000000.00
BIO.B income_statement (annual, 2024-12-31) — Operating Revenue: 2566500000.00
BIO.B balance_sheet (annual, 2024-12-31) — Ordinary Shares Number: 28011144.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Current Assets: 30700000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Current Borrowings: 1200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Current Liabilities: 147200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Equity Adjustments: -538200000.00
BIO.B income_statement (annual, 2024-12-31) — Other Income Expense: -2644600000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Intangible Assets: 293600000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Investments: 4839200000.00
BIO.B cash_flow (annual, 2024-12-31) — Other Non Cash Items: 49500000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Non Current Assets: 101900000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Non Current Liabilities: 177200000.00
BIO.B income_statement (annual, 2024-12-31) — Other Non Operating Income Expenses: 1600000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Properties: 1343700000.00
BIO.B balance_sheet (annual, 2024-12-31) — Other Short Term Investments: 1176400000.00
BIO.B balance_sheet (annual, 2024-12-31) — Payables: 153500000.00
BIO.B balance_sheet (annual, 2024-12-31) — Payables And Accrued Expenses: 277700000.00
BIO.B balance_sheet (annual, 2024-12-31) — Preferred Stock: 0.00
BIO.B balance_sheet (annual, 2024-12-31) — Prepaid Assets: 122600000.00
BIO.B income_statement (annual, 2024-12-31) — Pretax Income: -2342500000.00
BIO.B cash_flow (annual, 2024-12-31) — Proceeds From Stock Option Exercised: 19200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Properties: 0.00
BIO.B balance_sheet (quarterly, 2024-12-31) — Properties: 0.00
BIO.B income_statement (annual, 2024-12-31) — Provision For Doubtful Accounts: 0.00
BIO.B cash_flow (annual, 2024-12-31) — Provisionand Write Offof Assets: 0.00
BIO.B cash_flow (annual, 2024-12-31) — Purchase Of Business: 0.00
BIO.B cash_flow (annual, 2024-12-31) — Purchase Of Intangibles: -23400000.00
BIO.B cash_flow (quarterly, 2024-12-31) — Purchase Of Intangibles: 10000.00
BIO.B cash_flow (annual, 2024-12-31) — Purchase Of Investment: -1276600000.00
BIO.B cash_flow (annual, 2024-12-31) — Purchase Of PPE: -165600000.00
BIO.B balance_sheet (annual, 2024-12-31) — Raw Materials: 222000000.00
BIO.B balance_sheet (annual, 2024-12-31) — Receivables: 452500000.00
BIO.B income_statement (annual, 2024-12-31) — Reconciled Cost Of Revenue: 1187600000.00
BIO.B income_statement (annual, 2024-12-31) — Reconciled Depreciation: 151600000.00
BIO.B cash_flow (annual, 2024-12-31) — Repayment Of Debt: -400000.00
BIO.B cash_flow (annual, 2024-12-31) — Repurchase Of Capital Stock: -203600000.00
BIO.B income_statement (annual, 2024-12-31) — Research And Development: 295900000.00
BIO.B balance_sheet (annual, 2024-12-31) — Restricted Cash: 0.00
BIO.B balance_sheet (quarterly, 2024-12-31) — Restricted Cash: 0.00
BIO.B balance_sheet (annual, 2024-12-31) — Retained Earnings: 7416400000.00
BIO.B cash_flow (annual, 2024-12-31) — Sale Of Business: 0.00
BIO.B cash_flow (annual, 2024-12-31) — Sale Of Investment: 1305300000.00
BIO.B cash_flow (annual, 2024-12-31) — Sale Of PPE: 100000.00
BIO.B income_statement (annual, 2024-12-31) — Selling General And Administration: 814000000.00
BIO.B balance_sheet (annual, 2024-12-31) — Share Issued: 30265872.00
BIO.B income_statement (annual, 2024-12-31) — Special Income Charges: 0.00
BIO.B income_statement (quarterly, 2024-12-31) — Special Income Charges: 0.00
BIO.B cash_flow (annual, 2024-12-31) — Stock Based Compensation: 62300000.00
BIO.B balance_sheet (annual, 2024-12-31) — Stockholders Equity: 6569300000.00
BIO.B balance_sheet (annual, 2024-12-31) — Tangible Book Value: 5865200000.00
BIO.B income_statement (annual, 2024-12-31) — Tax Effect Of Unusual Items: -562903504.80
BIO.B income_statement (annual, 2024-12-31) — Tax Provision: -498300000.00
BIO.B income_statement (annual, 2024-12-31) — Tax Rate For Calcs: 0.21
BIO.B balance_sheet (annual, 2024-12-31) — Total Assets: 9364100000.00
BIO.B balance_sheet (annual, 2024-12-31) — Total Capitalization: 7769700000.00
BIO.B balance_sheet (annual, 2024-12-31) — Total Debt: 1374700000.00
BIO.B balance_sheet (annual, 2024-12-31) — Total Equity Gross Minority Interest: 6569300000.00
BIO.B income_statement (annual, 2024-12-31) — Total Expenses: 2297500000.00
BIO.B balance_sheet (annual, 2024-12-31) — Total Liabilities Net Minority Interest: 2794800000.00
BIO.B balance_sheet (annual, 2024-12-31) — Total Non Current Assets: 6333800000.00
BIO.B balance_sheet (annual, 2024-12-31) — Total Non Current Liabilities Net Minority Interest: 2327000000.00
BIO.B income_statement (annual, 2024-12-31) — Total Operating Income As Reported: 269000000.00
BIO.B balance_sheet (annual, 2024-12-31) — Total Tax Payable: 31200000.00
BIO.B income_statement (annual, 2024-12-31) — Total Unusual Items: -2646200000.00
BIO.B income_statement (annual, 2024-12-31) — Total Unusual Items Excluding Goodwill: -2646200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Treasury Shares Number: 2254728.00
BIO.B balance_sheet (annual, 2024-12-31) — Treasury Stock: 772100000.00
BIO.B cash_flow (annual, 2024-12-31) — Unrealized Gain Loss On Investment Securities: 2656800000.00
BIO.B balance_sheet (annual, 2024-12-31) — Work In Process: 243200000.00
BIO.B balance_sheet (annual, 2024-12-31) — Working Capital: 2562500000.00
BIO.B income_statement (annual, 2024-12-31) — Write Off: 0.00
BIO.B income_statement (quarterly, 2025-03-31) — +Operating Expense: 282300000.00
BIO.B income_statement (quarterly, 2025-03-31) — +Total Revenue: 585400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Accounts Payable: 137900000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Accounts Receivable: 424700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Additional Paid In Capital: 475700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Allowance For Doubtful Accounts Receivable: -7800000.00
BIO.B income_statement (quarterly, 2025-03-31) — Basic Average Shares: 27941000.00
BIO.B income_statement (quarterly, 2025-03-31) — Basic EPS: 2.29
BIO.B cash_flow (quarterly, 2025-03-31) — Beginning Cash Position: 489800000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Capital Expenditure: -34400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Capital Lease Obligations: 167600000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Capital Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Cash And Cash Equivalents: 521400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Cash Cash Equivalents And Short Term Investments: 1660400000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Financing Activities: -97700000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Investing Activities: 2900000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Cash Flow From Continuing Operating Activities: 129900000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Account Payable: 29800000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Income Tax Payable: 5700000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Inventory: -17900000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Other Current Assets: -5600000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Other Current Liabilities: -4800000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Other Working Capital: -800000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Payable: 35500000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Payables And Accrued Expense: 35500000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Receivables: 37200000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Tax Payable: 5700000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Change In Working Capital: 43600000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Changes In Account Receivables: 37200000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Changes In Cash: 35100000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Common Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Common Stock Equity: 6679400000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Common Stock Payments: -101900000.00
BIO.B income_statement (quarterly, 2025-03-31) — Cost Of Revenue: 279400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Current Accrued Expenses: 157400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Current Assets: 3036600000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Current Capital Lease Obligation: 41300000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Current Debt: 1200000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Current Debt And Capital Lease Obligation: 42500000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Current Liabilities: 506600000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Depreciation Amortization Depletion: 38100000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Depreciation And Amortization: 38100000.00
BIO.B income_statement (quarterly, 2025-03-31) — Diluted Average Shares: 27955000.00
BIO.B income_statement (quarterly, 2025-03-31) — Diluted EPS: 2.29
BIO.B income_statement (quarterly, 2025-03-31) — Diluted NI Availto Com Stockholders: 64000000.00
BIO.B income_statement (quarterly, 2025-03-31) — EBIT: 95400000.00
BIO.B income_statement (quarterly, 2025-03-31) — EBITDA: 133500000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Effect Of Exchange Rate Changes: -1800000.00
BIO.B cash_flow (quarterly, 2025-03-31) — End Cash Position: 523100000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Financing Cash Flow: -97700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Finished Goods: 315500000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Free Cash Flow: 95500000.00
BIO.B income_statement (quarterly, 2025-03-31) — Gain On Sale Of Security: 35000000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Gains Losses Not Affecting Retained Earnings: -409800000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Goodwill: 414600000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Goodwill And Other Intangible Assets: 710700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Gross Accounts Receivable: 432500000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Gross PPE: 681700000.00
BIO.B income_statement (quarterly, 2025-03-31) — Gross Profit: 306000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Interest Expense: 12000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Interest Expense Non Operating: 12000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Interest Income: 36200000.00
BIO.B income_statement (quarterly, 2025-03-31) — Interest Income Non Operating: 36200000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Inventory: 790100000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Invested Capital: 7881300000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Investing Cash Flow: 2900000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Investments And Advances: 4994200000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Long Term Capital Lease Obligation: 126300000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Long Term Debt: 1200700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Long Term Debt And Capital Lease Obligation: 1327000000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Long Term Debt Payments: -100000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Net Common Stock Issuance: -101900000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Net Debt: 680500000.00
BIO.B income_statement (quarterly, 2025-03-31) — Net Income: 64000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Net Income Common Stockholders: 64000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Net Income Continuous Operations: 64000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Net Income From Continuing And Discontinued Operation: 64000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Net Income From Continuing Operation Net Minority Interest: 64000000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Net Income From Continuing Operations: 64000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Net Income Including Noncontrolling Interests: 64000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Net Interest Income: 24200000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Net Investment Purchase And Sale: 37300000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Net Issuance Payments Of Debt: -100000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Net Long Term Debt Issuance: -100000.00
BIO.B income_statement (quarterly, 2025-03-31) — Net Non Operating Interest Income Expense: 24200000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Net PPE: 681700000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Net PPE Purchase And Sale: -34400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Net Tangible Assets: 5968700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Liabilities: 840800000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Non Current Deferred Taxes Liabilities: 840800000.00
BIO.B income_statement (quarterly, 2025-03-31) — Normalized EBITDA: 98500000.00
BIO.B income_statement (quarterly, 2025-03-31) — Normalized Income: 37141486.81
BIO.B cash_flow (quarterly, 2025-03-31) — Operating Cash Flow: 129900000.00
BIO.B income_statement (quarterly, 2025-03-31) — Operating Income: 23700000.00
BIO.B income_statement (quarterly, 2025-03-31) — Operating Revenue: 585400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Ordinary Shares Number: 27633212.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Current Assets: 36000000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Current Borrowings: 1200000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Current Liabilities: 131700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Equity Adjustments: -409800000.00
BIO.B income_statement (quarterly, 2025-03-31) — Other Income Expense: 35500000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Intangible Assets: 296100000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Investments: 4994200000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Other Non Cash Items: 700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Non Current Assets: 103700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Non Current Liabilities: 173100000.00
BIO.B income_statement (quarterly, 2025-03-31) — Other Non Operating Income Expenses: 500000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Properties: 681700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Other Short Term Investments: 1139000000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Payables: 175000000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Payables And Accrued Expenses: 332400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Preferred Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Prepaid Assets: 125400000.00
BIO.B income_statement (quarterly, 2025-03-31) — Pretax Income: 83400000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Proceeds From Stock Option Exercised: 4300000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Purchase Of Investment: -153400000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Purchase Of PPE: -34400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Raw Materials: 232100000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Receivables: 424700000.00
BIO.B income_statement (quarterly, 2025-03-31) — Reconciled Cost Of Revenue: 279400000.00
BIO.B income_statement (quarterly, 2025-03-31) — Reconciled Depreciation: 38100000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Repayment Of Debt: -100000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Repurchase Of Capital Stock: -101900000.00
BIO.B income_statement (quarterly, 2025-03-31) — Research And Development: 73500000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Retained Earnings: 7480400000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Sale Of Investment: 190700000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Sale Of PPE: 0.00
BIO.B income_statement (quarterly, 2025-03-31) — Selling General And Administration: 208800000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Share Issued: 30265870.00
BIO.B cash_flow (quarterly, 2025-03-31) — Stock Based Compensation: 15300000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Stockholders Equity: 6679400000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Tangible Book Value: 5968700000.00
BIO.B income_statement (quarterly, 2025-03-31) — Tax Effect Of Unusual Items: 8141486.81
BIO.B income_statement (quarterly, 2025-03-31) — Tax Provision: 19400000.00
BIO.B income_statement (quarterly, 2025-03-31) — Tax Rate For Calcs: 0.23
BIO.B balance_sheet (quarterly, 2025-03-31) — Total Assets: 9526900000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Total Capitalization: 7880100000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Total Debt: 1369500000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Total Equity Gross Minority Interest: 6679400000.00
BIO.B income_statement (quarterly, 2025-03-31) — Total Expenses: 561700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Total Liabilities Net Minority Interest: 2847500000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Total Non Current Assets: 6490300000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Total Non Current Liabilities Net Minority Interest: 2340900000.00
BIO.B income_statement (quarterly, 2025-03-31) — Total Operating Income As Reported: 23700000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Total Tax Payable: 37100000.00
BIO.B income_statement (quarterly, 2025-03-31) — Total Unusual Items: 35000000.00
BIO.B income_statement (quarterly, 2025-03-31) — Total Unusual Items Excluding Goodwill: 35000000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Treasury Shares Number: 2632658.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Treasury Stock: 866900000.00
BIO.B cash_flow (quarterly, 2025-03-31) — Unrealized Gain Loss On Investment Securities: -31800000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Work In Process: 242500000.00
BIO.B balance_sheet (quarterly, 2025-03-31) — Working Capital: 2530000000.00
BIO.B income_statement (quarterly, 2025-06-30) — +Operating Expense: 268200000.00
BIO.B income_statement (quarterly, 2025-06-30) — +Total Revenue: 651600000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Accounts Payable: 139300000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Accounts Receivable: 469900000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Additional Paid In Capital: 484600000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Allowance For Doubtful Accounts Receivable: -6800000.00
BIO.B income_statement (quarterly, 2025-06-30) — Basic Average Shares: 27226000.00
BIO.B income_statement (quarterly, 2025-06-30) — Basic EPS: 11.67
BIO.B cash_flow (quarterly, 2025-06-30) — Beginning Cash Position: 523100000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Capital Expenditure: -45700000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Capital Lease Obligations: 204100000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Capital Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Cash And Cash Equivalents: 369300000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Cash Cash Equivalents And Short Term Investments: 1373800000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Financing Activities: -136300000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Investing Activities: -115400000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Cash Flow From Continuing Operating Activities: 116500000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Account Payable: 4700000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Income Tax Payable: -18200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Inventory: 21600000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Other Current Assets: 19900000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Other Current Liabilities: 5300000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Other Working Capital: 69500000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Payable: -13500000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Payables And Accrued Expense: -13500000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Receivables: -25700000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Tax Payable: -18200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Change In Working Capital: 77100000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Changes In Account Receivables: -25700000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Changes In Cash: -135200000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Common Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Common Stock Equity: 7128700000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Common Stock Payments: -140200000.00
BIO.B income_statement (quarterly, 2025-06-30) — Cost Of Revenue: 306300000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Current Accrued Expenses: 157800000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Current Assets: 2811100000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Current Capital Lease Obligation: 39300000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Current Debt: 1300000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Current Debt And Capital Lease Obligation: 40600000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Current Liabilities: 548900000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Depreciation Amortization Depletion: 40600000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Depreciation And Amortization: 40600000.00
BIO.B income_statement (quarterly, 2025-06-30) — Diluted Average Shares: 27228000.00
BIO.B income_statement (quarterly, 2025-06-30) — Diluted EPS: 11.67
BIO.B income_statement (quarterly, 2025-06-30) — Diluted NI Availto Com Stockholders: 317800000.00
BIO.B income_statement (quarterly, 2025-06-30) — EBIT: 426600000.00
BIO.B income_statement (quarterly, 2025-06-30) — EBITDA: 467200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Effect Of Exchange Rate Changes: -16200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — End Cash Position: 371700000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Financing Cash Flow: -136300000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Finished Goods: 318500000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Free Cash Flow: 70800000.00
BIO.B income_statement (quarterly, 2025-06-30) — Gain On Sale Of Security: 334200000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Gains Losses Not Affecting Retained Earnings: -154100000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Goodwill: 581600000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Goodwill And Other Intangible Assets: 978500000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Gross Accounts Receivable: 476700000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Gross PPE: 740100000.00
BIO.B income_statement (quarterly, 2025-06-30) — Gross Profit: 345300000.00
BIO.B income_statement (quarterly, 2025-06-30) — Interest Expense: 12600000.00
BIO.B income_statement (quarterly, 2025-06-30) — Interest Expense Non Operating: 12600000.00
BIO.B income_statement (quarterly, 2025-06-30) — Interest Income: 14700000.00
BIO.B income_statement (quarterly, 2025-06-30) — Interest Income Non Operating: 14700000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Inventory: 798800000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Invested Capital: 8331100000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Investing Cash Flow: -115400000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Investments And Advances: 5576500000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Long Term Capital Lease Obligation: 164800000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Long Term Debt: 1201100000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Long Term Debt And Capital Lease Obligation: 1365900000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Long Term Debt Payments: -200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Net Common Stock Issuance: -140200000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Net Debt: 833100000.00
BIO.B income_statement (quarterly, 2025-06-30) — Net Income: 317800000.00
BIO.B income_statement (quarterly, 2025-06-30) — Net Income Common Stockholders: 317800000.00
BIO.B income_statement (quarterly, 2025-06-30) — Net Income Continuous Operations: 317800000.00
BIO.B income_statement (quarterly, 2025-06-30) — Net Income From Continuing And Discontinued Operation: 317800000.00
BIO.B income_statement (quarterly, 2025-06-30) — Net Income From Continuing Operation Net Minority Interest: 317800000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Net Income From Continuing Operations: 317800000.00
BIO.B income_statement (quarterly, 2025-06-30) — Net Income Including Noncontrolling Interests: 317800000.00
BIO.B income_statement (quarterly, 2025-06-30) — Net Interest Income: 2100000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Net Investment Purchase And Sale: 146900000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Net Issuance Payments Of Debt: -200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Net Long Term Debt Issuance: -200000.00
BIO.B income_statement (quarterly, 2025-06-30) — Net Non Operating Interest Income Expense: 2100000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Net PPE: 740100000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Net PPE Purchase And Sale: -45600000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Net Tangible Assets: 6150200000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Liabilities: 961000000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Non Current Deferred Taxes Liabilities: 961000000.00
BIO.B income_statement (quarterly, 2025-06-30) — Normalized EBITDA: 133000000.00
BIO.B income_statement (quarterly, 2025-06-30) — Normalized Income: 61134400.00
BIO.B cash_flow (quarterly, 2025-06-30) — Operating Cash Flow: 116500000.00
BIO.B income_statement (quarterly, 2025-06-30) — Operating Income: 77100000.00
BIO.B income_statement (quarterly, 2025-06-30) — Operating Revenue: 651600000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Ordinary Shares Number: 27062235.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Current Assets: 19000000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Current Borrowings: 1300000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Current Liabilities: 175000000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Equity Adjustments: -154100000.00
BIO.B income_statement (quarterly, 2025-06-30) — Other Income Expense: 334800000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Intangible Assets: 396900000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Investments: 5576500000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Other Non Cash Items: 3500000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Non Current Assets: 107900000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Non Current Liabilities: 209600000.00
BIO.B income_statement (quarterly, 2025-06-30) — Other Non Operating Income Expenses: 600000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Properties: 740100000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Other Short Term Investments: 1004500000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Payables: 175500000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Payables And Accrued Expenses: 333300000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Preferred Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Prepaid Assets: 149600000.00
BIO.B income_statement (quarterly, 2025-06-30) — Pretax Income: 414000000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Proceeds From Stock Option Exercised: 4200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Purchase Of Investment: -153200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Purchase Of PPE: -45700000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Raw Materials: 231900000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Receivables: 469900000.00
BIO.B income_statement (quarterly, 2025-06-30) — Reconciled Cost Of Revenue: 306300000.00
BIO.B income_statement (quarterly, 2025-06-30) — Reconciled Depreciation: 40600000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Repayment Of Debt: -200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Repurchase Of Capital Stock: -140200000.00
BIO.B income_statement (quarterly, 2025-06-30) — Research And Development: 60500000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Retained Earnings: 7798200000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Sale Of Investment: 300100000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Sale Of PPE: 100000.00
BIO.B income_statement (quarterly, 2025-06-30) — Selling General And Administration: 207700000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Share Issued: 30265870.00
BIO.B cash_flow (quarterly, 2025-06-30) — Stock Based Compensation: 11900000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Stockholders Equity: 7128700000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Tangible Book Value: 6150200000.00
BIO.B income_statement (quarterly, 2025-06-30) — Tax Effect Of Unusual Items: 77534400.00
BIO.B income_statement (quarterly, 2025-06-30) — Tax Provision: 96200000.00
BIO.B income_statement (quarterly, 2025-06-30) — Tax Rate For Calcs: 0.23
BIO.B balance_sheet (quarterly, 2025-06-30) — Total Assets: 10214100000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Total Capitalization: 8329800000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Total Debt: 1406500000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Total Equity Gross Minority Interest: 7128700000.00
BIO.B income_statement (quarterly, 2025-06-30) — Total Expenses: 574500000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Total Liabilities Net Minority Interest: 3085400000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Total Non Current Assets: 7403000000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Total Non Current Liabilities Net Minority Interest: 2536500000.00
BIO.B income_statement (quarterly, 2025-06-30) — Total Operating Income As Reported: 77100000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Total Tax Payable: 36200000.00
BIO.B income_statement (quarterly, 2025-06-30) — Total Unusual Items: 334200000.00
BIO.B income_statement (quarterly, 2025-06-30) — Total Unusual Items Excluding Goodwill: 334200000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Treasury Shares Number: 3203635.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Treasury Stock: 1000000000.00
BIO.B cash_flow (quarterly, 2025-06-30) — Unrealized Gain Loss On Investment Securities: -334400000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Work In Process: 248400000.00
BIO.B balance_sheet (quarterly, 2025-06-30) — Working Capital: 2262200000.00
BIO.B income_statement (quarterly, 2025-09-30) — +Operating Expense: 279500000.00
BIO.B income_statement (quarterly, 2025-09-30) — +Total Revenue: 653000000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Accounts Payable: 128800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Accounts Receivable: 464700000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Additional Paid In Capital: 461900000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Allowance For Doubtful Accounts Receivable: -6200000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Beginning Cash Position: 371700000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Capital Expenditure: -31700000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Capital Lease Obligations: 192600000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Capital Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Cash And Cash Equivalents: 395800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Cash Cash Equivalents And Short Term Investments: 1418600000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Financing Activities: -52500000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Investing Activities: -43000000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Cash Flow From Continuing Operating Activities: 120900000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Account Payable: -33300000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Income Tax Payable: 400000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Inventory: 13600000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Other Current Assets: 2100000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Other Current Liabilities: -1000000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Other Working Capital: -88400000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Payable: -32900000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Payables And Accrued Expense: -32900000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Receivables: 4200000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Tax Payable: 400000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Change In Working Capital: -102400000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Changes In Account Receivables: 4200000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Changes In Cash: 25400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Common Stock: 0.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Common Stock Equity: 6736800000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Common Stock Payments: -53400000.00
BIO.B income_statement (quarterly, 2025-09-30) — Cost Of Revenue: 309600000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Current Accrued Expenses: 182800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Current Assets: 2842000000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Current Capital Lease Obligation: 36800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Current Debt: 1300000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Current Debt And Capital Lease Obligation: 38100000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Current Liabilities: 522300000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Depreciation Amortization Depletion: 44200000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Depreciation And Amortization: 44200000.00
BIO.B income_statement (quarterly, 2025-09-30) — Diluted NI Availto Com Stockholders: -341900000.00
BIO.B income_statement (quarterly, 2025-09-30) — EBIT: -418800000.00
BIO.B income_statement (quarterly, 2025-09-30) — EBITDA: -374600000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Effect Of Exchange Rate Changes: 1100000.00
BIO.B cash_flow (quarterly, 2025-09-30) — End Cash Position: 398200000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Financing Cash Flow: -52500000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Finished Goods: 309500000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Free Cash Flow: 89200000.00
BIO.B income_statement (quarterly, 2025-09-30) — Gain On Sale Of Security: -491400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Gains Losses Not Affecting Retained Earnings: -166800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Goodwill: 578700000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Goodwill And Other Intangible Assets: 967100000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Gross Accounts Receivable: 470900000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Gross PPE: 720500000.00
BIO.B income_statement (quarterly, 2025-09-30) — Gross Profit: 343400000.00
BIO.B income_statement (quarterly, 2025-09-30) — Interest Expense: 12300000.00
BIO.B income_statement (quarterly, 2025-09-30) — Interest Expense Non Operating: 12300000.00
BIO.B income_statement (quarterly, 2025-09-30) — Interest Income: 13700000.00
BIO.B income_statement (quarterly, 2025-09-30) — Interest Income Non Operating: 13700000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Inventory: 783200000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Invested Capital: 7939500000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Investing Cash Flow: -43000000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Investments And Advances: 5057800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Long Term Capital Lease Obligation: 155800000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Long Term Debt: 1201400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Long Term Debt And Capital Lease Obligation: 1357200000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Long Term Debt Payments: 0.00
BIO.B cash_flow (quarterly, 2025-09-30) — Net Business Purchase And Sale: -1800000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Net Common Stock Issuance: -53400000.00
BIO.B balance_sheet (quarterly, 2025-09-30) — Net Debt: 806900000.00
BIO.B income_statement (quarterly, 2025-09-30) — Net Income: -341900000.00
BIO.B income_statement (quarterly, 2025-09-30) — Net Income Common Stockholders: -341900000.00
BIO.B income_statement (quarterly, 2025-09-30) — Net Income Continuous Operations: -341900000.00
BIO.B income_statement (quarterly, 2025-09-30) — Net Income From Continuing And Discontinued Operation: -341900000.00
BIO.B income_statement (quarterly, 2025-09-30) — Net Income From Continuing Operation Net Minority Interest: -341900000.00
BIO.B cash_flow (quarterly, 2025-09-30) — Net Income From Continuing Operations: -341900000.00